Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24325990 | 0.89 | HCRTR2 (0.43) | HCRTR2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL31228510 | 0.89 | HCRTR2 (0.44) | HCRTR2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL31228444 | 0.86 | HCRTR2 (0.45) | HCRTR2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL27013002 | 0.86 | HCRTR2 (0.43) | HCRTR2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL31153995 | 0.84 | HCRTR2 (0.40) | HCRTR2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL31153860 | 0.83 | GPR119 (0.40) | HCRTR2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL30723478 | 0.83 | NR1H2 (0.38) | HCRTR2MEN1KMT2AUSP30GPR119 | |
| SCHEMBL29504656 | 0.83 | KDM1A (0.46) | HCRTR2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL1150256 | 0.82 | HCRTR2 (0.41) | HCRTR2TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL15317914 | 0.81 | NR1H2 (0.38) | HCRTR2MEN1KMT2AUSP30GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790058-A | Fused cyclic KRAS inhibitors for the treatment of diseases | 荣山医药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | HCRTR2 564/4885TSHR 197/4885ALDH1A1 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.